Browsed by
Tag: Facility

Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation An

Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation An

  Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research
    Facility to Enhance Development of Next Generation Antibody Radiation
              Conjugates Leveraging Its Proprietary AWE Platform

PR Newswire

NEW YORK, Oct. 14, 2020

NEW YORK, Oct. 14, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE
AMERICAN: ATNM) ("Actinium" or the "Company") today announced the launch of
its new research and development lab facility in New York City.  This new
research facility expands Actinium's internal R&D capabilities and will be
focused on developing novel Antibody Radiation Conjugate (ARC) candidates, ARC
therapeutic combination strategies, and supporting AWE platform research
collaborations. Actinium's R&D efforts will employ a multidisciplinary
approach leveraging its team's expertise and experience in cancer cell
biology, radiochemistry, radiation sciences, immunology and oncology drug
development.  The proprietary AWE technology platform, protected by over one
hundred and twenty-five patents, is the foundation for Actinium's R&D and
exploits multiple different radioisotope payloads including the potent
alpha-emitter, Actinium-225.  

(PRNewsfoto/Actinium Pharmaceuticals, Inc.)

This new research facility will function under the guidance of Dr. Dale
Ludwig, Ph.D. the Company's Chief Scientific & Technology Officer, who has
over twenty-five years of oncology discovery research and development
experience, including supporting the development and launch of Erbitux®,
Cyramza^TM, Portrazza®, and Lartruvo^TM as well as the clinical advancement of
at least 10 additional therapeutic antibodies and Antibody Drug Conjugates
while at Eli Lilly and, previously, ImClone Systems Inc.  The research
facility will be managed and staffed by Ph.D. level scientists who will
contribute their respective expertise in areas of drug discovery, radiation
chemistry, and translational research to advance novel ARC programs and
investigations into combination therapeutic strategies.

"Our new research facility will allow us to significantly accelerate our
preclinical and clinical development of novel ARC programs and investigate
mechanistic ARC therapeutic combinations, which utilize our expertise in
radioimmunobiology, our AWE Technology Platform capabilities, 
Read the rest
Oxford Finance Provides $55 Million Credit Facility to SpendMend

Oxford Finance Provides $55 Million Credit Facility to SpendMend

ALEXANDRIA, Va. and GRAND RAPIDS, Mich., Oct. 8, 2020 /PRNewswire/ — Oxford Finance LLC (“Oxford”), a specialty finance firm that provides senior debt to healthcare services and life sciences companies worldwide, today announced the closing of a $55 million senior credit facility and revolving line of credit to SpendMend (or “the Company”), a portfolio company of Sheridan Capital Partners.

The proceeds were used to refinance existing debt, fund the acquisition of Turnkey Pharmacy Solutions (“Turnkey”) and Elevate340B (“Elevate”), and provide ongoing working capital. Oxford Finance is the sole lead arranger and administrative agent in this transaction.

Established in 1993, SpendMend is the leading outsourced provider of cost cycle management services and tech-enabled solutions to the healthcare market. A majority of the nation’s top healthcare systems partner with SpendMend to improve patient care through innovative cost-savings solutions.

“SpendMend is a recognized leader in cost cycle management,” said Tracy S. Maziek, head of healthcare services at Oxford Finance. “The Company provides tangible value and bottom-line impact to a complex industry operating on thin margins. The continued growth of these businesses, in spite of the global impacts of COVID, strengthened our conviction and validated the compelling value propositions of these businesses. Oxford is happy to be working with the Sheridan team once again and to now be supporting SpendMend.”

“The acquisition of Turnkey and Elevate broadens our suite of offerings providing compliance, optimization and growth services for the complex and critical 340B programs at health systems,” stated Dan Geehoed, CEO of SpendMend. “Oxford provided a flexible financing solution to support this acquisition and will be a valuable partner to support our continued growth.”

“Oxford was able to deliver a compelling proposal on an expedited timeline and with a high degree of certainty,” added Nick Rowland, principal at Sheridan Capital Partners. “We are pleased

Read the rest